Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TTK | P33981 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20696763 | 0.89 | TYK2 (0.41) | TYK2PARP1KAT2B | |
| SCHEMBL20689216 | 0.83 | TYK2 (0.42) | TYK2PARP1MALT1KDM4ESMN1; SMN2 | |
| SCHEMBL16812533 | 0.73 | TYK2 (0.56) | TYK2PARP1KDM4ESMN1; SMN2 | |
| SCHEMBL21227386 | 0.70 | TYK2 (0.55) | TYK2KDM4E | |
| SCHEMBL20688025 | 0.66 | TYK2 (0.38) | TYK2SMN1; SMN2KAT2BBRD9 | |
| SCHEMBL20687635 | 0.66 | TYK2 (0.38) | TYK2KDM4ESMN1; SMN2KAT2BBRD9 | |
| SCHEMBL20688221 | 0.66 | KAT2B (0.38) | TYK2SMN1; SMN2KAT2BBRD9 | |
| SCHEMBL16812418 | 0.66 | TYK2 (0.54) | TYK2PARP1KDM4E | |
| SCHEMBL22252591 | 0.65 | KAT2B (0.43) | TYK2SMN1; SMN2KAT2BBRD9 | |
| SCHEMBL22272968 | 0.65 | TYK2 (0.51) | TYK2SMN1; SMN2KAT2BBRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | Nimbus Lakshimi, Inc. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-15 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248797-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | TYK2 1/4885PARP1 939/4885MALT1 636/4885 |
| US-10562907-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | TYK2 1/4885PARP1 939/4885MALT1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.